Publications 2015

Publications auxquelles l’Aretasc a participé en 2015 :

Interest of short androgen deprivation therapy (ADT) combined with radiotherapy (RT) as salvage for biological relapse (BR) after radical prostatectomy (RP) results of GetuG-AFU 16 phase III randomized trial

asco 2015 abst 5006

Pepita Etude prospective de cohorte évaluant l’efficacité et la tolérance d’un traitement de 2ed ligne par Tarceva chez de patients atteints d’un cancer bronchique non à petites cellules(CBNPC) de type épidermoïde avancé ou métastatique

Janvier-Février 2015 : 19 congres de pneumologie française

Erlotinib in 2nd line in advanced squamous : N abstract WCLC 2015 (total 490 words for 500 words allowed SCLS

Final results of the PEPITA cohort : A.Vergnenègre, O.Molinier, I.Monnet, Paris-France

Epidermal growth factor receptor (EGFR) pathway biomarkers in the randomized Phase III trial of Erlotinib versus Observation in Ovarian cancer patients with no evidence of disease progression after first-line platinum-based chemotherapy

Despierre E, Vergote I, Anderson R.
Targeted Oncology : Dec 2015, volume 10,issue 4

Final Analysis :Ten year follow-up of BCIRG 006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AT> T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC >TH) with docetaxel, carboplatin and trastuzumab TCH) in HER2+ early breast cancer

Slamon D, EiermannW, Robert N, Giermek J, on behallf of the BCIRG – 006 investigators SABC 8-12 Decembre 2015

Multicentre randomised phase II trial of gemcitabine+ platinum, with or without trastuzumab in advanced or metastatic urothelial carcinoma overexpressing HER2

Eur J Cancer 2015 Jan 15 ; 51(1)45-54
S.Oudart, S.Culine, Y.Vano

Minimal impact of adjuvant exemstane or tamoxifen treatment on mammographic breast density in postmenospausal breast cancer patients

A Dutch TEAM trial analysis.
Acta Oncol, 2015 Mar ; 54(3) : 349-60